NCT02760238 Myeloproliferative Neoplasms (MPNs) Patient Registry
| NCT ID | NCT02760238 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Primary Myelofibrosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2015-04 |
| Primary Completion | 2027-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2015-04 with a primary completion date of 2027-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.
Eligibility Criteria
Inclusion Criteria: Diagnosis of one of the following myeloproliferative neoplasms (MPNs): * Atypical CML (aCML) * Chronic eosinophilic leukemia-not otherwise specified (CEL, NOS), * Chronic myelomonocytic leukemia (CMML) * Chronic neutrophilic leukemia (CNL), * Essential thrombocythemia (ET), * Juvenile myelomonocytic leukemia (JMML), * Mastocytosis, MPN unclassifiable * MPN/MDS unclassifiable, * Primary myelofibrosis (PMF), * Post-essential thrombocythemia myelofibrosis (post-ET MF), * Post-polycythemia vera MF (post-PV MF) * Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) Exclusion Criteria: * None
Contact & Investigator
Vikas Gupta, MD
PRINCIPAL INVESTIGATOR
University Health Network, Toronto
Frequently Asked Questions
Who can join the NCT02760238 clinical trial?
This trial is open to participants of all sexes, studying Primary Myelofibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02760238 currently recruiting?
Yes, NCT02760238 is actively recruiting participants. Contact the research team at vikas.gupta@uhn.ca for enrollment information.
Where is the NCT02760238 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT02760238 clinical trial?
NCT02760238 is sponsored by University Health Network, Toronto. The principal investigator is Vikas Gupta, MD at University Health Network, Toronto. The trial plans to enroll 5,000 participants.